Related Resources
\n- \n
- breast cancer awareness articles \n
- diagnostic test preparation guide \n
- diagnostic test comparison resources \n
- breast cancer diagnostic guidance \n
Test-Specific Disclaimer
\nThis content is for informational purposes only and does not substitute professional medical advice. IHC test interpretation must be performed by qualified pathologists and treating specialists. Please refer to our disclaimer policy.
\n","image":["/images/healthcarentsickcarestore.shop/images/product/ihc-panel-test-for-breast-cancer-1.avif"],"sku":"ihc-panel-test-for-breast-cancer","brand":{"@type":"Brand","name":"healthcare nt sickcare"},"offers":{"@type":"AggregateOffer","lowPrice":4499,"highPrice":8199,"priceCurrency":"USD","availability":"https://schema.org/InStock","url":"https://healthcarentsickcarestore.shop/products/ihc-panel-test-for-breast-cancer","offerCount":3}}
IHC Panel Test for Breast Cancer
About IHC Panel Test for Breast Cancer
The IHC Panel Test for Breast Cancer is a tissue-based tumour marker test performed using immunohistochemistry (IHC), a laboratory method that detects specific proteins in biopsy samples to classify breast tumours. This panel helps determine hormone sensitivity, tumour aggressiveness and treatment suitability.
At healthcare nt sickcare in Pune, this test supports oncologists and pathologists in confirming breast cancer subtype and guiding targeted therapy decisions. Sample processing is available through our Direct Walk-in Facility with coordinated tissue sample handling from hospitals across Pune.
What does this IHC panel evaluate?
This panel identifies key breast cancer markers to confirm tumour type and likely treatment response.
Markers Covered in This Panel
HER2, ER, PR, Ki-67 and p53 markers are analysed to determine hormone receptor status, tumour growth rate and cancer behaviour.
Specimen: Tissue preserved in 10% neutral buffered formalin, usually provided as a Paraffin Block / FFPE (Formalin-Fixed Paraffin-Embedded) tissue.
Frequently Asked Questions
This test is advised after a breast biopsy to confirm tumour subtype and guide treatment planning.
It identifies hormone receptor and HER2 status, helping doctors choose targeted and hormonal therapies.
No fasting is required as this test is performed on tissue biopsy samples.
Breast lump, nipple discharge, skin changes or suspicious imaging findings may require this evaluation.
Related Resources
- breast cancer awareness articles
- diagnostic test preparation guide
- diagnostic test comparison resources
- breast cancer diagnostic guidance
Test-Specific Disclaimer
This content is for informational purposes only and does not substitute professional medical advice. IHC test interpretation must be performed by qualified pathologists and treating specialists. Please refer to our disclaimer policy.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
About IHC Panel Test for Breast Cancer
The IHC Panel Test for Breast Cancer is a tissue-based tumour marker test performed using immunohistochemistry (IHC), a laboratory method that detects specific proteins in biopsy samples to classify breast tumours. This panel helps determine hormone sensitivity, tumour aggressiveness and treatment suitability.
At healthcare nt sickcare in Pune, this test supports oncologists and pathologists in confirming breast cancer subtype and guiding targeted therapy decisions. Sample processing is available through our Direct Walk-in Facility with coordinated tissue sample handling from hospitals across Pune.
What does this IHC panel evaluate?
This panel identifies key breast cancer markers to confirm tumour type and likely treatment response.
Markers Covered in This Panel
HER2, ER, PR, Ki-67 and p53 markers are analysed to determine hormone receptor status, tumour growth rate and cancer behaviour.
Specimen: Tissue preserved in 10% neutral buffered formalin, usually provided as a Paraffin Block / FFPE (Formalin-Fixed Paraffin-Embedded) tissue.
Frequently Asked Questions
This test is advised after a breast biopsy to confirm tumour subtype and guide treatment planning.
It identifies hormone receptor and HER2 status, helping doctors choose targeted and hormonal therapies.
No fasting is required as this test is performed on tissue biopsy samples.
Breast lump, nipple discharge, skin changes or suspicious imaging findings may require this evaluation.
Related Resources
- breast cancer awareness articles
- diagnostic test preparation guide
- diagnostic test comparison resources
- breast cancer diagnostic guidance
Test-Specific Disclaimer
This content is for informational purposes only and does not substitute professional medical advice. IHC test interpretation must be performed by qualified pathologists and treating specialists. Please refer to our disclaimer policy.
